Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for physician-led pharmaceutical clinical research, health checkups, and specific health guidance; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.

Soiken Holdings Inc.

総医研ホールディングス is involved in commercializing research results in medical science to contribute to people's health and safety in living.

	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24
net income	82M -	332M 304.88%	226M 31.93%	169M 25.22%	13.74M 91.87%	195.46M 1,322.38%	287.02M 46.84%	-44.37M 115.46%	-527.10M 1,087.85%	39.21M 107.44%	-87M 321.88%
depreciation and amortization					4.19M -	5.03M 20.09%	7.55M 50.17%	8.02M 6.19%	6.21M 22.54%	6.72M 8.17%
deferred income tax
stock based compensation
change in working capital
accounts receivables
inventory
accounts payables
other working capital
other non cash items	-82M -	-332M 304.88%	-226M 31.93%	-169M 25.22%	-9.56M 94.35%	-190.44M 1,892.84%	-279.47M 46.75%	52.39M 118.75%	533.30M 917.95%	-32.49M 106.09%	87M 367.74%
net cash provided by operating activities					8.37M -	10.05M 20.09%	15.10M 50.17%	16.03M 6.19%	12.42M 22.54%	13.43M 8.17%
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
debt repayment
common stock issued
common stock repurchased
dividends paid
other financing activites
net cash used provided by financing activities
effect of forex changes on cash
net change in cash					-1.06B -	570.43M 154.05%	-37.70M 106.61%	451.16M 1,296.59%	-881.60M 295.41%	-355.60M 59.66%
cash at beginning of period					6.02B -	4.96B 17.54%	5.53B 11.50%	5.49B 0.68%	5.95B 8.21%	5.06B 14.83%
cash at end of period					4.96B -	5.53B 11.50%	5.49B 0.68%	5.95B 8.21%	5.06B 14.83%	4.71B 7.02%
operating cash flow					8.37M -	10.05M 20.09%	15.10M 50.17%	16.03M 6.19%	12.42M 22.54%	13.43M 8.17%
capital expenditure
free cash flow					8.37M -	10.05M 20.09%	15.10M 50.17%	16.03M 6.19%	12.42M 22.54%	13.43M 8.17%

2385

COM:SOIKEN

総医研ホールディングス

Last Close

138.00

25/11 06:45

Market Cap

4.37B

Beta: -

Volume Today

13.90K

Avg: -

Preview